Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marcela Valderrama Maus, M.D., Ph.D.


This page shows the publications co-authored by Marcela Maus and Irene Scarfo.
Connection Strength

  1. Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. Cancer Cell. 2020 02 10; 37(2):143-144.
    View in: PubMed
    Score: 0.858
  2. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260.
    View in: PubMed
    Score: 0.844
  3. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. Front Oncol. 2019; 9:259.
    View in: PubMed
    Score: 0.811
  4. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018 10 04; 132(14):1495-1506.
    View in: PubMed
    Score: 0.773
  5. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017; 5:28.
    View in: PubMed
    Score: 0.702
  6. Blockade or Deletion of IFN? Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discov. 2022 Mar 01; 3(2):136-153.
    View in: PubMed
    Score: 0.247
  7. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019 11 14; 7(1):304.
    View in: PubMed
    Score: 0.211
  8. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res. 2019 12 01; 25(23):7046-7057.
    View in: PubMed
    Score: 0.208
  9. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058.
    View in: PubMed
    Score: 0.206
  10. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Adv Sci (Weinh). 2019 Dec; 6(23):1901829.
    View in: PubMed
    Score: 0.052
  11. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. 2019 05 07; 10(1):2087.
    View in: PubMed
    Score: 0.051
  12. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019 03; 37(3):276-282.
    View in: PubMed
    Score: 0.050
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.